

Datasheet

SARS-CoV-2 S1-Receptor-Binding Domain (RBD) – Delta (B.1.617.2)_HEK

Description:


A recombinant form of the Spike protein receptor binding domain (RBD) from the SARS-CoV-2 Delta variant (B.1.617.2), which is produced under serum-free conditions in human embryonic kidney, HEK293 cells.

RBD-Delta (B.1.617.2) variant; containing mutations L452R and T478K.

Protein design and manufacturing process is based on RBD protein (aa 319-541). The protein includes a C-terminal hexa-histidine-tag and is purified using immobilized metal exchange chromatography (IMAC) and preparative SEC (for polishing).

Product Code:	BSV-COV-PR-98HEK
Expression System:	Mammalian; HEK
Protein Accession Number:	QHD43416.1 (GenBank)
Amino Acids:	319-541
Mutations:	L452R, T478K
Mature Protein N-Term:	Arg319 (Predicted)
Tag:	6 x His-Tag; C-terminal
Expected Molecular Weight:	26 kDa (glycosylated form runs at 25-40 kDa in gel electrophoresis)
Formulation:	Liquid, 20 mM NaPP, 300 mM NaCl pH 7.2
Concentration:	> 0.5 mg/ml
Purity:	> 90% (via analytical CGE under reducing conditions)

The product is for further research use or manufacturing only.



SARS-CoV-2 receptor-binding domains (RBD-Wuhan, Delta, Delta plus, Lambda, Eta and Mu) recombinantly expressed in HEK cells tested as solid phase bound capture antigens at 2 µg/mL in an in-house SARS-CoV-2 IgG ELISA.

14 SARS-CoV-2 positive patient serum samples (obtained before October 2020) were applied. The line indicates the median of the absorbance values.